The recent cyberattack on Medicare by an AI agent has uncovered significant vulnerabilities in Australia's government technology systems, referred to as 'tech debt.' In response, the Home Affairs Department has instructed all federal agencies to undertake a comprehensive review of their outdated technology. Each agency must develop a strategy to minimize reliance on legacy systems to manage security risks effectively. This move highlights the urgent need for modernization across government platforms, which could result in substantial expenses for taxpayers.
A major hospital and radiology network implemented Palantir's AI-powered scheduling system to improve efficiency. However, nurses and staff report that the software has led to increased scheduling errors, heightened burnout, and growing frustration, raising concerns about patient safety.
Epic, the leading developer behind the popular MyChart patient portal, has decided to temporarily stop releasing new product features. The decision comes as the company shifts focus to resolving critical security issues that could potentially expose patient information. Over the coming weeks, Epic's teams will prioritize patching these vulnerabilities to reinforce data safety and protect users of its health information systems.
Back in 2009, sequencing Euan Ashley’s entire genome required nearly a year and the effort of 30 specialists. Fast forward to 2026, and Claude accomplished the same task in just 30 minutes, costing approximately $5. This drastic reduction in time and expense highlights the incredible advancements in genomic technology. However, with rapid analysis capabilities now accessible, establishing clear standards for interpreting and using these results is becoming increasingly critical.
Google's advanced AI model has been recognized by the Centers for Disease Control as the top performer in predicting hospitalizations due to the flu. This breakthrough in health forecasting demonstrates AI's growing impact on public health management.
Google DeepMind unveils SynthID Bio, a new watermarking technology designed for AI-created proteins that does not compromise their biological functions. Discover the full details in their research report.
Federal health authorities are launching new strategies to enhance the pace of clinical research, aiming to stay competitive on a global scale, especially against countries like China.
At a MAHA Institute event, Kennedy and other experts emphasized the importance of making health data more accessible. They highlighted how unlocking this data can accelerate research on vaccines, chronic diseases, and autism, ultimately benefiting public health outcomes.
In March, Janice Malone noticed alarming reports of suspicious activity affecting her nonprofit, Vivian's Door. The Alabama-based organization supports underserved and minority-owned businesses and often handles sensitive financial data. Unexpectedly, people worldwide reported receiving fraudulent emails soliciting money that Janice never sent. This breach prompted the organization's IT team to take systems offline for three days to identify and seal vulnerabilities.
The AI revolution is swiftly advancing beyond digital realms into tangible innovations, boosting infrastructure from chips to data centers. At the 2026 World Economic Forum, Nvidia's Jensen Huang framed AI as a five-layer system: energy, chips, cloud, models, and applications, where the final layer delivers real-world impact. Among all fields, medicine stands out for its potential to turn AI-driven capacity into profound economic and social value.
In 2024, the U.S. spent $5.3 trillion on healthcare, including substantial investment in prescription drugs, highlighting the immense resources directed towards disease treatment. Medicines that significantly alter widespread diseases can enhance lives, reduce healthcare burdens, and provide lucrative returns for developers and investors. The blockbuster success of drugs like Eli Lilly's tirzepatide, with $36.5 billion in combined annual sales, illustrates this scale.
AI promises to transform drug discovery by helping scientists navigate complex decisions, rank promising paths, and design smarter experiments based on large data analysis. Despite challenges like complex biology and uneven data quality, the most impactful AI systems integrate continuous learning loops from experiments, accelerating innovation and improving drug candidates' chances.
Though clinical proof remains limited, progress in areas such as AI for mass spectrometry has already sped up drug discovery timelines, uncovering new therapeutic prospects. The key measure of AI's success will be its ability to enhance real-world clinical outcomes, not just laboratory results.
For stakeholders, the critical question is whether AI can improve decision-making throughout drug development, leading to better trial results and patient benefits. The hope is that AI-driven breakthroughs will emerge more frequently, bringing millions healthier years and renewed hope sooner than ever before.
Authors: Viswa Colluru, CEO of Enveda, and Bigyan Bista, Head of Capital Formation at Enveda.
